The role of ubiquitin-proteasome pathway in oncogenic signaling

Cancer Biology and Therapy

Volumn 1, Issue 4, 2002, Pages 337-341

  Fuchs, Serge Y ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cancer; Oncogene; Proteasome; Signal transduction; Ubiquitin

Indexed keywords

BETA CATENIN; CTNNB1 PROTEIN, HUMAN; CYSTEINE PROTEINASE; CYTOSKELETON PROTEIN; DNA BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYMPHOID ENHANCER FACTOR 1; MESSENGER RNA; MULTIENZYME COMPLEX; PROTEASOME; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA; UBIQUITIN;

CELL DIFFERENTIATION; CELL DIVISION; CELL SURVIVAL; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; NEOPLASM; REVIEW; SIGNAL TRANSDUCTION;

BETA CATENIN; CELL DIFFERENTIATION; CELL DIVISION; CELL SURVIVAL; CYSTEINE ENDOPEPTIDASES; CYTOSKELETAL PROTEINS; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOID ENHANCER-BINDING FACTOR 1; MULTIENZYME COMPLEXES; NEOPLASMS; NF-KAPPA B; PROTEASOME ENDOPEPTIDASE COMPLEX; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TRANSFORMING GROWTH FACTOR BETA; UBIQUITIN;

EID: 0242344011     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Weissman AM. Themes and variations on ubiquitiylation. Nat Rev Mol Cell Biol 2001; 2:169-78.
2. Schwartz AL, Ciechanover A. The ubiquitin-proteasome pathway and pathogenesis of human diseases. Annu Rev Med 1999; 50:57-74. (Pubitemid 29117052)
3. Pickart CM. Ubiquitin enters the new millennium. Mol Cell 2001; 8:499-504.
4. Joazeiro CA, Weissman AM. RING finger proteins: mediators of ubiquitin ligase activity. Cell 2000; 102:549-52.
5. Tyers M, Jorgensen P. Proteolysis and the cell cycle: with this RING I do thee destroy. Curr Opin Genet Dev 2000; 10:54-64. (Pubitemid 30113706)
6. Kondo K, Kaelin WG, Jr. The von Hippel-Lindau tumor suppressor gene. Exp Cell Res 2001; 264:117-25.
7. Deshaies RJ. SCF and Cullin/Ring H2-based ubiquitin ligases. Annu Rev Cell Dev Biol 1999; 15:435-67. (Pubitemid 32250383)
8. DeSalle LM, Pagano M. Regulation of the G1 to S transition by the ubiquitin pathway. FEBS Lett 2001; 490:179-89. (Pubitemid 32171937)
9. Blagosklonny MV. Do VHL and HIF-1 mirror p53 and Mdm-2? Degradation-transactivation loops of oncoproteins and tumor suppressors. Oncogene 2001; 20:395-8. (Pubitemid 32142329)
10. Polakis P. The oncogenic activation of β-catenin. Curr Opin Genet Dev 1999; 9:15-21.
11. Polakis P. Wnt signaling and cancer. Genes Dev 2000; 14:1837-51. (Pubitemid 30639518)
12. Liu C, Li Y, Semenov M, Han C, Baeg GH, Tan Y, et al. Control of β-Catenin Phosphorylation/ Degradation by a Dual-Kinase Mechanism. Cell 2002; 108:837-47. (Pubitemid 34327534)
13. Gao ZH, Seeling JM, Hill V, Yochum A, Virshup DM. Casein kinase I phosphorylates and destabilizes the β-catenin degradation complex. Proc Natl Acad Sci USA 2002; 99:1182-7. (Pubitemid 34136467)
14. Liu J, Stevens J, Rote CA, Yost HJ, Hu Y, Neufeld KL, et al. Siah-1 mediates a novel β-catenin degradation pathway linking p53 to the adenomatous polyposis coli protein. Mol Cell 2001; 7:927-36. (Pubitemid 32525740)
15. Matsuzawa SI, Reed JC. Siah-1, SIP, and Ebi collaborate in a novel pathway for β-catenin degradation linked to p53 responses. Mol Cell 2001; 7:915-26. (Pubitemid 32525739)
16. Sadot E, Geiger B, Oren M, Ben-Ze'ev A. Down-regulation of b-catenin by activated p53. Mol Cell Biol 2001; 21:6768-81.
17. Sparks AB, Morin PJ, Vogelstein B, Kinzler KW. Mutational analysis of the APC/ β-catenin/Tcf pathway in colorectal cancer. Cancer Res 1998; 58:1130-4. (Pubitemid 28183198)
18. Damalas A, Ben-Ze'ev A, Simcha I, Shtutman M, Leal JF, Zhurinsky J, et al. Excess β-catenin promotes accumulation of transcriptionally active p53. Embo J 1999; 18:3054-63.
19. Damalas A, Kahan S, Shtutman M, Ben-Ze'ev A, Oren M. Deregulated β-catenin induces a p53- and ARF-dependent growth arrest and cooperates with Ras in transformation. Embo J 2001; 20:4912-22.
20. Mayo MW, Baldwin AS. The transcription factor NF-κB: control of oncogenesis and cancer therapy resistance. Biochim Biophys Acta 2000; 1470:M55-62.
21. Foo SY, Nolan GP. NF-kB to the rescue: RELs, apoptosis and cellular transformation. Trends Genet 1999; 15:229-35. (Pubitemid 29278676)
22. de Martin R, Schmid JA, Hofer-Warbinek R. The NF-kB/Rel family of transcription factors in oncogenic transformation and apoptosis. Mutat Res 1999; 437:231-43.
23. Ben-Neriah Y. Regulatory functions of ubiquitination in the immune system. Nat Immunol 2002; 3:20-6. (Pubitemid 34065613)
24. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu Rev Immunol 2000; 18:621-63. (Pubitemid 30365393)
25. Chen F, Castranova V, Shi X. New insights into the role of nuclear factor-κB in cell growth regulation. Am J Pathol 2001; 159:387-97. (Pubitemid 32751067)
26. Spiegelman VS, Slaga TJ, Pagano M, Minamoto T, Ronai Z, Fuchs SY. Wnt/β-catenin signaling induces the expression and activity of b-TrCP ubiquitin ligase receptor. Mol Cell 2000; 5:877-82.
27. Bhatia N, Herter JR, Slaga TJ, Fuchs SY, Spiegelman VS. Mouse homologue of HOS (mHOS) is overexpressed in skin tumors and implicated in constitutive activation of NFκB. Oncogene 2002; 21:1501-1509. (Pubitemid 34226137)
28. Ciechanover A, Gonen H, Bercovich B, Cohen S, Fajerman I, Israel A, et al. Mechanisms of ubiquitin-mediated, limited processing of the NF-κB1 precursor protein p105. Biochimie 2001; 83:341-9. (Pubitemid 32293655)
29. Echarri A, Pendergast AM. Activated c-Abl is degraded by the ubiquitin-dependent proteasome pathway. Curr Biol 2001; 11:1759-65. (Pubitemid 33092163)
30. Harris KF, Shoji I, Cooper EM, Kumar S, Oda H, Howley PM. Ubiquitin-mediated degradation of active Src tyrosine kinase. Proc Natl Acad Sci USA 1999; 96:13738-43.
31. Rao N, Ghosh AK, Ota S, Zhou P, Reddi AL, Hakezi K, et al. The non-receptor tyrosine kinase Syk is a target of Cbl-mediated ubiquitylation upon B-cell receptor stimulation. Embo J 2001; 20:7085-95. (Pubitemid 34062300)
32. Oda H, Kumar S, Howley PM. Regulation of the Src family tyrosine kinase Blk through E6AP-mediated ubiquitination. Proc Natl Acad Sci USA 1999; 96:9557-62. (Pubitemid 29398769)
33. Thien CB, Langdon WY. Cbl: many adaptations to regulate protein tyrosine kinases. Nat Rev Mol Cell Biol 2001; 2:294-307.
34. Levkowitz G, Waterman H, Zamir E, Kam Z, Oved S, Langdon WY, et al. c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes Dev 1998; 12:3663-74. (Pubitemid 29019647)
35. Joazeiro CA, Wing SS, Huang H, Leverson JD, Hunter T, Liu YC. The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase. Science 1999; 286:309-12.
36. Peschard P, Fournier TM, Lamorte L, Naujokas MA, Band H, Langdon WY, et al. Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Mol Cell 2001; 8:995-1004. (Pubitemid 34031802)
37. Wilhelmsen K, Burkhalter S, van der Geer P. C-Cbl binds the CSF-1 receptor at tyrosine 973, a novel phosphorylation site in the receptor's carboxy-terminus. Oncogene 2002; 21:1079-89. (Pubitemid 34174520)
38. Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology 2001; 61:1-13. (Pubitemid 33033419)
39. Waterman H, Yarden Y. Molecular mechanisms underlying endocytosis and sorting of ErbB receptor tyrosine kinases. FEBS Lett 2001; 490:142-52. (Pubitemid 32171933)
40. Thien CB, Walker F, Langdon WY. RING finger mutations that abolish c-Cbl-directed polyubiquitination and downregulation of the EGF receptor are insufficient for cell transformation. Mol Cell 2001; 7:355-65. (Pubitemid 32206503)
41. Katzmann DJ, Babst M, Emr SD. Ubiquitin-dependent sorting into the multivesicular body pathway requires the function of a conserved endosomal protein sorting complex, ESCRT-I. Cell 2001; 106:145-55. (Pubitemid 32772626)
42. Li L, Cohen SN. Tsg101: a novel tumor susceptibility gene isolated by controlled homozygous functional knockout of allelic loci in mammalian cells. Cell 1996; 85:319-29. (Pubitemid 26160704)
43. Massague J, Blain SW, Lo RS. TGFb signaling in growth control, cancer, and heritable disorders. Cell 2000; 103:295-309.
44. Ebisawa T, Fukuchi M, Murakami G, Chiba T, Tanaka K, Imamura T, et al. Smurf1 interacts with transforming growth factor-β type I receptor through Smad7 and induces receptor degradation. J Biol Chem 2001; 276:12477-80.
45. Bonni S, Wang HR, Causing CG, Kavsak P, Stroschein SL, Luo K, et al. TGF-β induces assembly of a Smad2-Smurf2 ubiquitin ligase complex that targets SnoN for degradation. Nat Cell Biol 2001; 3:587-95. (Pubitemid 32536856)
46. Wan Y, Liu X, Kirschner MW. The anaphase-promoting complex mediates TGF-β signaling by targeting SnoN for destruction. Mol Cell 2001; 8:1027-39. (Pubitemid 34031805)
47. Stroschein SL, Bonni S, Wrana JL, Luo K. Smad3 recruits the anaphase-promoting complex for ubiquitination and degradation of SnoN. Genes Dev 2001; 15:2822-36. (Pubitemid 33042053)
48. Zhang Y, Chang C, Gehling DJ, Hemmati-Brivanlou A, Derynck R. Regulation of Smad degradation and activity by Smurf2, an E3 ubiquitin ligase. Proc Natl Acad Sci USA 2001; 98:974-9. (Pubitemid 32121172)
49. Xu J, Attisano L. Mutations in the tumor suppressors Smad2 and Smad4 inactivate transforming growth factor b signaling by targeting Smads to the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 2000; 97:4820-5. (Pubitemid 30238641)
50. Lin X, Liang M, Feng XH. Smurf2 is a ubiquitin E3 ligase mediating proteasome-dependent degradation of Smad2 in transforming growth factor-β signaling. J Biol Chem 2000; 275:36818-22. (Pubitemid 32002092)
51. Lo RS, Massague J. Ubiquitin-dependent degradation of TGF-β-activated smad2. Nat Cell Biol 1999; 1:472-8.
52. Scheffner M. Ubiquitin, E6-AP, and their role in p53 inactivation. Pharmacol Ther 1998; 78:129-39.
53. Querido E, Blanchette P, Yan Q, Kamura T, Morrison M, Boivin D, et al. Degradation of p53 by adenovirus E4orf6 and E1B55K proteins occurs via a novel mechanism involving a Cullin-containing complex. Genes Dev 2001; 15:3104-17. (Pubitemid 33115675)
54. Treier M, Staszewski LM, Bohmann D. Ubiquitin-dependent c-Jun degradation in vivo is mediated by the delta domain. Cell 1994; 78:787-98. (Pubitemid 24294454)
55. Gavine PR, Neil JC, Crouch DH. Protein stabilization: a common consequence of mutations in independently derived v-Myc alleles. Oncogene 1999; 18:7552-8. (Pubitemid 30035056)
56. Acquaviva C, Ferrara P, Bossis G, Brockly F, Salvat C, Jariel-Encontre I, et al. Degradation of cellular and viral Fos proteins. Biochimie 2001; 83:357-62. (Pubitemid 32293657)
57. Acquaviva C, Salvat C, Brockly F, Bossis G, Ferrara P, Piechaczyk M, et al. Cellular and viral Fos proteins are degraded by different proteolytic systems. Oncogene 2001; 20:942-50. (Pubitemid 32207111)
58. Wolff L. Myb-induced transformation. Crit Rev Oncog 1996; 7:245-60. (Pubitemid 27362414)
59. Bies J, Wolff L. Oncogenic activation of c-Myb by carboxyl-terminal truncation leads to decreased proteolysis by the ubiquitin-26S proteasome pathway. Oncogene 1997; 14:203-12. (Pubitemid 27068306)
60. Bies J, Nazarov V, Wolff L. Alteration of proteolytic processing of c-Myb as a consequence of its truncation in murine myeloid leukemia. Leukemia 1999; 13 Suppl 1:S116-7.
61. Bahram F, von der Lehr N, Cetinkaya C, Larsson LG. c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover. Blood 2000; 95:2104-10. (Pubitemid 30151652)
62. Gregory MA, Hann SR. c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells. Mol Cell Biol 2000; 20:2423-35. (Pubitemid 30152050)
63. Salghetti SE, Kim SY, Tansey WP. Destruction of Myc by ubiquitin-mediated proteolysis: cancer-associated and transforming mutations stabilize Myc. Embo J 1999; 18:717-26. (Pubitemid 29057256)
64. Sears R, Leone G, DeGregori J, Nevins JR. Ras enhances Myc protein stability. Mol Cell 1999; 3:169-79. (Pubitemid 29292618)
65. Klein E, Teramoto N, Gogolak P, Nagy N, Bjorkholm M. LMP-1, the Epstein-Barr virus-encoded oncogene with a B cell activating mechanism similar to CD40. Immunol Lett 1999; 68:147-54. (Pubitemid 29265666)
66. Knecht H, Berger C, Rothenberger S, Odermatt BF, Brousset P. The role of Epstein-Barr virus in neoplastic transformation. Oncology 2001; 60:289-302. (Pubitemid 32623442)
67. Aviel S, Winberg G, Massucci M, Ciechanover A. Degradation of the epstein-barr virus latent membrane protein 1 (LMP1) by the ubiquitin-proteasome pathway. Targeting via ubiquitination of the N-terminal residue. J Biol Chem 2000; 275:23491-9. (Pubitemid 30624630)
68. Blake SM, Eliopoulos AG, Dawson CW, Young LS. The transmembrane domains of the EBV-encoded latent membrane protein 1 (LMP1) variant CAO regulate enhanced signalling activity. Virology 2001; 282:278-87. (Pubitemid 32881155)
69. Jenkins PJ, Farrell PJ. Are particular Epstein-Barr virus strains linked to disease? Semin Cancer Biol 1996; 7:209-15.
70. Rolfe M, Chiu MI, Pagano M. The ubiquitin-mediated proteolytic pathway as a therapeutic area. J Mol Med 1997; 75:5-17. (Pubitemid 27067134)
71. Shah SA, Potter MW, Callery MP. Ubiquitin proteasome pathway: implications and advances in cancer therapy. Surg Oncol 2001; 10:43-52. (Pubitemid 33086839)
72. Adams J. Proteasome inhibition in cancer: development of PS-341. Semin Oncol 2001; 28:613-9. (Pubitemid 33134421)